Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Study of Anti-tumour Effects and Safety of Prolarix™ in Hepatocellular Carcinoma

This study has been terminated.
(Study terminated prematurely by sponsor for business reason. One patient was enrolled.)
Information provided by (Responsible Party):
BTG International Inc. Identifier:
First received: September 3, 2008
Last updated: May 3, 2016
Last verified: May 2016

This an open-label study designed to evaluate the anti-tumour activity and safety of Prolarix in subjects with advanced hepatocellular carcinoma.

Prolarix is a chemotherapy comprised of tretazicar as prodrug and caricotamide as co-substrate for the endogenous enzyme, NQO2.

Condition Intervention Phase
Hepatocellular Carcinoma
Drug: Prolarix (tretazicar co-administered with caricotamide)
Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase 2 Study of the Anti-tumour Activity and Safety of Prolarix™ in Hepatocellular Carcinoma (HCC)

Further study details as provided by BTG International Inc.:

Primary Outcome Measures:
  • Overall Best Tumor Response Rate (Proportion of Subjects With Complete or Partial Response) as Defined by Modified RECIST [ Time Frame: every 6 weeks until progression ]

Secondary Outcome Measures:
  • Disease Control Rate Defined as the Proportion of Subjects With Either Complete or Partial Response or Stable Disease [ Time Frame: Approximately 12 weeks or more after first treatment with Prolarix ]
  • Time to Tumour Progression [ Time Frame: Every 3 weeks until progression ]
  • Post-treatment Changes in the Amount of Contrast-enhancing and Non-contrast-enhancing Tumour [ Time Frame: Every 6 weeks until progression ]
  • Changes in Alpha Fetoprotein [ Time Frame: Baseline, every 3 weeks until progression ]
  • Adverse Events [ Time Frame: Until progression ]
  • Changes in Laboratory Measurements [ Time Frame: Baseline and every 3 weeks until progression ]

Enrollment: 1
Study Start Date: September 2008
Study Completion Date: August 2009
Primary Completion Date: June 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1 Drug: Prolarix (tretazicar co-administered with caricotamide)
Prolarix (26.6 mg/m2 tretazicar co-administered with 200 mg/m2 caricotamide) administered intravenously every 21 days until disease progression
Other Name: Prolarix

Detailed Description:

The primary objective of this study is to evaluate the anti-tumour effects of treatment with Prolarix in subjects with advanced HCC (Child-Pugh A and B only).

All subjects will receive an IV infusion of Prolarix once every 21 days until disease progression is observed.

Subjects will have CT scans for tumour measurements before starting treatment with Prolarix and every 6 weeks until disease progression.

Subjects will undergo evaluation for safety (adverse events, vital signs, clinical laboratory measurements, weight, ECG) every 21 days until disease progression.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Subject must be at least 18 years of age.
  • Subject must have a histologic or cytologic diagnosis of HCC and be considered unsuitable for resection or other potentially curative options (eg, liver transplant, curative radiofrequency ablation).
  • Subject must have a measurable lesion by RECIST on CT scan in at least one site which has not received radiation or any other local therapy [eg, transcatheter arterial chemoembolisation (TACE), radiofrequency ablation, local injection]. (Note: Subjects who have received local therapies will be allowed to participate, provided that they have a target lesion which has not been subjected to local therapy. Subjects who have received TACE must have a target lesion outside of the vascular territory subjected to chemoembolisation.)
  • Subject has an Eastern Cooperative Oncology Group (ECOG) Performance status of 0 or 1.
  • Subject has had no other active malignancy within the past three years [other than non melanomatous skin cancer or carcinoma in situ (CIS) of the breast, bladder, or uterine cervix. Subjects with Ta (non-invasive papillary carcinoma) or Tis (sessile carcinoma in situ) bladder cancer are allowed].
  • Subject has a minimum life expectancy of at least three months as determined by the investigator.
  • Subject has adequate bone marrow function (ie, haemoglobin ≥9 g/dL, granulocytes ≥1500/mm3, platelets ≥75,000/mm3).
  • Prothrombin time (PT)-international normalised ratio (INR) ≤2.3 or PT ≤6 seconds above control. (Note: Subjects who are being therapeutically anticoagulated with an agent such as warfarin or heparin will be allowed to participate provided that their INR is between 2.0 and 3.0.
  • Subject has adequate renal function (ie, serum creatinine is normal or calculated creatinine clearance is ≥60 mL/min).
  • Subject has adequate hepatic function (ie, bilirubin ≤2x upper limit of normal (ULN); AST ALT, and alkaline phosphatase ≤5xULN). (Also see exclusion for Child-Pugh class C below).
  • Male subjects and females of childbearing potential must agree to use an adequate method of contraception from the time of initiation of treatment through study participation and for 3 months after release from the study.
  • Subject is able to give informed consent.

Exclusion Criteria:

  • Any prior or current systemic pharmacotherapy for HCC (cytotoxic, targeted or biologic). (Note: TACE is not considered to be systemic pharmacotherapy for the purpose of this study).
  • Subject has an absolute contraindication to receiving CT contrast media. (Note: Subjects with a history of minor contrast reactions may be pre-medicated prior to contrast administration in accordance with local or institutional practice).
  • Subject has Child-Pugh Class C hepatic impairment.
  • Subject has received an investigational drug within 30 days of enrolment in the study.
  • Females of childbearing potential unless using adequate contraception.
  • Pregnant or lactating females.
  • Major variceal bleeding in the last 30 days.
  • Subjects with a known history of human immunodeficiency virus (HIV) infection.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00746590

Cliniques Universitaires Saint-Luc
Brussels, Belgium, 1200
Sponsors and Collaborators
BTG International Inc.
Study Director: Claire Daugherty, MS BTG International Inc.
  More Information

Responsible Party: BTG International Inc. Identifier: NCT00746590     History of Changes
Other Study ID Numbers: PR003-CLN-pro001
Study First Received: September 3, 2008
Results First Received: May 3, 2016
Last Updated: May 3, 2016
Individual Participant Data  
Plan to Share IPD: Yes

Keywords provided by BTG International Inc.:
hepatocellular carcinoma
liver cancer
Phase 2

Additional relevant MeSH terms:
Carcinoma, Hepatocellular
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Liver Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Liver Diseases
Antineoplastic Agents processed this record on April 28, 2017